(Q42830264)

English

Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial

scientific article published on 6 November 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

atrial fibrillation

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

4

object named as

Lars Wallentin

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Hans-Christoph Diener

1

object named as

Hans-Christoph Diener

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

9

object named as

Salim Yusuf

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Michael D. Ezekowitz

3

object named as

Michael D Ezekowitz

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Muredach P. Reilly

5

object named as

Paul A Reilly

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

6

object named as

Sean Yang

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

author name string

Stuart J Connolly

2

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Denis Xavier

7

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Giuseppe Di Pasquale

8

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

RE-LY study group

10

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

publication date

6 November 2010

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Lancet Neurology

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

1157-1163

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Atrial fibrillation as an independent risk factor for stroke: the Framingham Study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970274-X

7 January 2021

based on heuristic

inferred from DOI database lookup

New oral anticoagulants in atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970274-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970274-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Dabigatran versus warfarin in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970274-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Stroke Prevention In Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970274-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970274-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Validation of Clinical Classification Schemes for Predicting Stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970274-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970274-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970274-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970274-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970274-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1474-4422(10)70274-X

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42830264&oldid=1971492685"